Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Leerink Partners
Leerink Partners upgraded shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) from a market perform rating to an outperform rating in a research note published on Wednesday morning,Benzinga reports. They currently have $10.00 target price on the stock, up from their prior target price of $4.00. Other equities research analysts have also issued research reports […]
Leerink Partners upgraded shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) from a market perform rating to an outperform rating in a research note published on Wednesday morning,Benzinga reports. They currently have $10.00 target price on the stock, up from their prior target price of $4.00. Other equities research analysts have also issued research reports […]
